

Chapter 14

Atopic Dermatitis (Atopic Eczema)

Donald Y.M. Leung, Lawrence F. Eichenfield,
& Mark Boguniewicz

REFERENCES

1. Eichenfield LF et al: Consensus conference on pediatric atopic dermatitis. *J Am Acad Dermatol* **49**:1088, 2003 [PMID 14639390]
2. Schultz-Larsen F, Hanifin JM: Epidemiology of atopic dermatitis. *Immunol Allergy Clin N Am* **22**:1, 2002
3. Odhiambo JA et al: Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. *J Allergy Clin Immunol* **124**:1251, 2009 [PMID 20004783]
4. Tay YK et al: The prevalence and descriptive epidemiology of atopic dermatitis in Singapore school children. *Br J Dermatol* **146**:101, 2002 [PMID 11841373]
5. Eichenfield LF et al: Atopic dermatitis and asthma: Parallels in the evolution of treatment. *Pediatrics* **111**:608, 2003 [PMID 12612244]
6. von Mutius E: Gene-environment interactions in asthma. *J Allergy Clin Immunol* **123**:3, 2009 [PMID 19130922]
7. Strachan DP: Hay fever, hygiene, and household size. *BMJ* **299**:1259, 1989 [PMID 2513902]
8. Bieber T: Atopic dermatitis. *N Engl J Med* **358**:1483, 2008 [PMID 18385500]
9. Cork MJ et al: Epidermal barrier dysfunction in atopic dermatitis. *J Invest Dermatol* **129**:1892, 2009 [PMID 19494826]
10. O'Regan GM et al: Filaggrin in atopic dermatitis. *J Allergy Clin Immunol* **122**:689, 2008 [PMID 18774165]
11. Spergel JM et al: Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice. *J Clin Invest* **101**:1614, 1998 [PMID 9541491]
12. Hamid Q, Boguniewicz M, Leung DY: Differential *in situ* cytokine gene expression in acute versus chronic atopic dermatitis. *J Clin Invest* **94**:870, 1994 [PMID 8040343]
13. Werfel T: The role of leukocytes, keratinocytes, and allergen-specific IgE in the development of atopic dermatitis. *J Invest Dermatol* **129**:1878, 2009 [PMID 19357709]
14. Sonkoly E et al: IL-31: A new link between T cells and pruritus in atopic skin inflammation. *J Allergy Clin Immunol* **117**:411, 2006 [PMID 16461142]
15. Bratton DL et al: Granulocyte macrophage colony-stimulating factor contributes to enhanced monocyte survival in chronic atopic dermatitis. *J Clin Invest* **95**:211, 1995 [PMID 7814618]
16. Toda M et al: Polarized *in vivo* expression of IL-11 and IL-17 between acute and chronic skin lesions. *J Allergy Clin Immunol* **111**:875, 2003 [PMID 12704372]
17. Leung DY et al: New insights into atopic dermatitis. *J Clin Invest* **113**:651, 2004 [PMID 14991059]
18. Novak N et al: Dendritic cells: Bridging innate and adaptive immunity in atopic dermatitis. *J Allergy Clin Immunol* **125**:50, 2010 [PMID 20109736]
19. Wollenberg A et al: Plasmacytoid dendritic cells: A new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. *J Invest Dermatol* **119**:1096, 2002 [PMID 12445198]
20. Novak N et al: Characterization of FcεRI-bearing CD123 blood dendritic cell antigen-2 plasmacytoid dendritic cells in atopic dermatitis. *J Allergy Clin Immunol* **114**:364, 2004 [PMID 15316517]
21. Baud O et al: Treatment of the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) by allogeneic bone marrow transplantation. *N Engl J Med* **344**:1758, 2001 [PMID 11396442]
22. Hoetzenecker W et al: Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis. *J Allergy Clin Immunol* **115**:1276, 2005 [PMID 15940147]
23. Akdis CA, Blaser K, Akdis M: Apoptosis in tissue inflammation and allergic disease. *Curr Opin Immunol* **16**:717, 2004 [PMID 15511663]

24. Chatila TA: Role of regulatory T cells in human diseases. *J Allergy Clin Immunol* **116**:949, 2005 [PMID 16275360]
25. Verhagen J et al: Absence of T-regulatory cell expression and function in atopic dermatitis skin. *J Allergy Clin Immunol* **117**:176, 2006 [PMID 16387603]
26. Cardona ID: Staphylococcal enterotoxin B inhibits regulatory T cells by inducing glucocorticoid-induced TNF receptor-related protein ligand on monocytes. *J Allergy Clin Immunol* **117**:688, 2006 [PMID 16522472]
27. Di Cesare A, Di Meglio P, Nestle FO: A role for Th17 cells in the immunopathogenesis of atopic dermatitis? *J Invest Dermatol* **128**:2569, 2008 [PMID 18927538]
28. Burgler S et al: Differentiation and functional analysis of human T(H)17 cells. *J Allergy Clin Immunol* **123**:588, 2009 [PMID 19178935]
29. Guttman-Yassky E et al: Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. *J Immunol* **181**:7420, 2008 [PMID 18981165]
30. Eyerich K et al: IL-17 in atopic eczema: Linking allergen-specific adaptive and microbial-triggered innate immune response. *J Allergy Clin Immunol* **123**:59, 2009 [PMID 19056110]
31. Nograles KE et al: IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. *J Allergy Clin Immunol* **123**:1244, 2009 [PMID 19439349]
32. Giustizieri ML et al: Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines. *J Allergy Clin Immunol* **107**:871, 2001 [PMID 11344355]
33. Ziegler SF, Artis D: Sensing the outside world: TSLP regulates barrier immunity. *Nat Immunol* **11**:289, 2010 [PMID 20300138]
34. Zhang Z et al: Thymic stromal lymphopoietin overproduced by keratinocytes in mouse skin aggravates experimental asthma. *Proc Natl Acad Sci USA* **106**(5):1536-1541, 2009
35. Demehri S et al: Skin-derived TSLP triggers progression from epidermal-barrier defects to asthma. *PLoS Biol* **7**(5):e1000067, 2009 [Epub May 19, 2009]
36. De Benedetto A et al: Atopic dermatitis: A disease caused by innate immune defects? *J Invest Dermatol* **129**:14, 2009 [PMID 19078985]
37. Barnes KC: An update on the genetics of atopic dermatitis: Scratching the surface in 2009. *J Allergy Clin Immunol* **125**:16, 2010 [PMID 20109730]
38. Rodriguez E et al: Meta-analysis of filaggrin polymorphisms in eczema and asthma: Robust risk factors in atopic disease. *J Allergy Clin Immunol* **123**:1361, 2009 [PMID 19501237]
39. Klein PA, Clark RA: An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. *Arch Dermatol* **135**:1522, 1999 [PMID 10606058]
40. Yu B et al: Polymorphisms in human histamine receptor H4 gene are associated with atopic dermatitis. *Br J Dermatol* 2010 [Epub ahead of print]
41. Eichenfield LF et al: Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. *J Am Acad Dermatol* **46**:495, 2002 [PMID 11907497]
42. Van Der Meer JB et al: The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. The Netherlands Adult Atopic Dermatitis Study Group. *Br J Dermatol* **140**:1114, 1999 [PMID 10354080]
43. Bilsborough J et al: IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. *J Allergy Clin Immunol* **117**:418, 2006 [PMID 16461143]
44. Steinhoff M, Biro T: A TR(I)P to pruritus research: Role of TRPV3 in inflammation and itch. *J Invest Dermatol* **129**:531, 2009 [PMID 19209153]
45. Hanifin JM, Rakja G: Diagnostic features of atopic dermatitis. *Acta Derm Venereol* **92**:44, 1980
46. Williams HC et al: The UK Working Party's Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. *Br J Dermatol* **131**:383, 1994 [PMID 7918015]
47. Zhang Q et al: Combined immunodeficiency associated with DOCK8 mutations. *N Engl J Med* **361**:2046, 2009 [PMID 19776401]
48. Boguniewicz M, Leung DY: Recent insights into atopic dermatitis and implications for management of infectious complications. *J Allergy Clin Immunol* **125**:4, 2010 [PMID 20109729]
49. Schlievert PM et al: Secreted virulence factor comparison between methicillin-resistant and methicillin-sensitive *Staphylococcus aureus*, and its relevance to atopic dermatitis. *J Allergy Clin Immunol* **125**:39, 2010 [PMID 20109735]

50. Müller S et al: Association of Filaggrin loss-of-function-mutations with atopic dermatitis and asthma in the Early Treatment of the Atopic Child (ETAC) population. *Pediatr Allergy Immunol* **20**:358, 2009 [PMID 19538357]
51. Krakowski AC, Eichenfield LF, Dohil MA: Management of atopic dermatitis in the pediatric population. *Pediatrics* **122**:812, 2008 [PMID 18829806]
52. Nicol NH, Boguniewicz M: Successful strategies in atopic dermatitis management. *Dermatol Nurs Suppl.*:3, 2008 [PMID 19102292]
53. Akdis CA et al: Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. *J Allergy Clin Immunol* **118**:152, 2006 [PMID 16815151]
54. Kezic S et al: Loss-of-function mutations in the filaggrin gene lead to reduced level of natural moisturizing factor in the stratum corneum. *J Invest Dermatol* **128**:2117, 2008 [PMID 18305568]
55. Chiang C, Eichenfield LF: Quantitative assessment of combination bathing and moisturizing regimens on skin hydration in atopic dermatitis. *Pediatr Dermatol* **26**:273, 2009 [PMID 19706087]
56. Boguniewicz M et al: MAS063DP is effective monotherapy for mild to moderate atopic dermatitis in infants and children: A multicenter, randomized, vehicle-controlled study. *J Pediatr* **152**:854, 2008 [PMID 18492531]
57. Sugarman JL, Parish LC: Efficacy of a lipid-based barrier repair formulation in moderate-to-severe pediatric atopic dermatitis. *J Drugs Dermatol* **8**:1106, 2009 [PMID 20027938]
58. Boguniewicz M et al: A multidisciplinary approach to evaluation and treatment of atopic dermatitis. *Semin Cutan Med Surg* **27**:115, 2008 [PMID 18620133]
59. Devillers AC, Oranje AP: Efficacy and safety of 'wet-wrap' dressings as an intervention treatment in children with severe and/or refractory atopic dermatitis: A critical review of the literature. *Br J Dermatol* **154**:579, 2006 [PMID 16536797]
60. Jensen JM et al: Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. *J Allergy Clin Immunol* **123**:1124, 2009 [PMID 19410693]
61. Friedlander SF, Hebert AA, Allen DB: Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. *J Am Acad Dermatol* **46**:387, 2002 [PMID 11862174]
62. Dohil MA, Alvarez-Connelly E, Eichenfield LF: Fluocinolone acetonide 0.01% in peanut oil: Safety and efficacy data in the treatment of childhood atopic dermatitis in infants as young as 3 months of age. *Pediatr Dermatol* **26**:262, 2009 [PMID 19706085]
63. Eichenfield L et al: Evaluation of adrenal suppression of a lipid enhanced, topical emollient cream formulation of hydrocortisone butyrate 0.1% in treating children with atopic dermatitis. *Pediatr Dermatol* **24**:81, 2007 [PMID 17300659]
64. Eichenfield LF et al: Effect of desonide hydrogel 0.05% on the hypothalamic-pituitary-adrenal axis in pediatric subjects with moderate to severe atopic dermatitis. *Pediatr Dermatol* **24**:289, 2007 [PMID 17542883]
65. Eichenfield LF, Miller BH: Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from 3 months of age. *J Am Acad Dermatol* **54**:715, 2006 [PMID 16546598]
66. Berth-Jones J et al: Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: Randomised, double blind, parallel group study. *BMJ* **326**:1367, 2003 [PMID 12816824]
67. Wollenberg A, Bieber T: Proactive therapy of atopic dermatitis—An emerging concept. *Allergy* **64**:276, 2009 [PMID 19076538]
68. Hultsch T, Kapp A, Spergel J: Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. *Dermatology* **211**:174, 2005 [PMID 16088174]
69. Hanifin JM et al: Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. *J Am Acad Dermatol* **53**:S186, 2005 [PMID 16021174]
70. Papp KA et al: Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: A two-year study. *J Am Acad Dermatol* **52**:240, 2005 [PMID 15692468]
71. Queille-Roussel C et al: The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: A randomized, double-blind controlled study. *Br J Dermatol* **144**:507, 2001 [PMID 11260007]
72. Paul C et al: Safety and tolerability of 1% pimecrolimus cream among infants: Experience with 1133 patients treated for up to 2 years. *Pediatrics* **117**:e118, 2006 [PMID 16361223]

73. Berger TG et al: The use of topical calcineurin inhibitors in dermatology: Safety concerns. Report of the American Academy of Dermatology Association Task Force. *J Am Acad Dermatol* **54**:818, 2006 [PMID 16635663]
74. Arellano FM et al: Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. *J Invest Dermatol* **127**:808, 2007 [PMID 17096020]
75. Breneman D et al: Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: A randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle. *J Am Acad Dermatol* **58**:990, 2008 [PMID 18359127]
76. Paller AS et al: Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: A new paradigm for use. *Pediatrics* **122**:e1210, 2008 [PMID 19015204]
77. Zug KA et al: Contact allergy in children referred for patch testing: North American Contact Dermatitis Group data, 2001–2004. *Arch Dermatol* **144**:1329, 2008 [PMID 18936397]
78. Leung DY: Infection in atopic dermatitis. *Curr Opin Pediatr* **15**:399, 2003 [PMID 12891053]
79. Koning S et al: Interventions for impetigo. *Cochrane Database Syst Rev* CD003261, 2004 [PMID 15106198]
80. Niebuhr M et al: Antibiotic treatment of cutaneous infections with *Staphylococcus aureus* in patients with atopic dermatitis: Current antimicrobial resistances and susceptibilities. *Exp Dermatol* **17**:953, 2008 [PMID 18557929]
81. Huang JT et al: Treatment of *Staphylococcus aureus* colonization in atopic dermatitis decreases disease severity. *Pediatrics* **123**:e808, 2009 [PMID 19403473]
82. Langeveld-Wildschut EG et al: Modulation of the atopy patch test reaction by topical corticosteroids and tar. *J Allergy Clin Immunol* **106**:737, 2000 [PMID 11031345]
83. Paghдал KV, Schwartz RA: Topical tar: Back to the future. *J Am Acad Dermatol* **61**:294, 2009 [PMID 19185953]
84. Lyakhovitsky A et al: Low-dose methotrexate treatment for moderate-to-severe atopic dermatitis in adults. *J Eur Acad Dermatol Venereol* **24**:43, 2010 [PMID 19552716]
85. Berth-Jones J et al: Azathioprine in severe adult atopic dermatitis: A double-blind, placebo-controlled, crossover trial. *Br J Dermatol* **147**:324, 2002 [PMID 12174106]
86. Hon KL et al: Efficacy and tolerability at 3 and 6 months following use of azathioprine for recalcitrant atopic dermatitis in children and young adults. *J Dermatolog Treat* **20**:141, 2009 [PMID 18951236]
87. Wolverson SE: Optimizing clinical use of azathioprine with newer pharmacogenetic data. *Arch Dermatol* **145**:707, 2009 [PMID 19528429]
88. Hanifin JM et al: Recombinant interferon gamma therapy for atopic dermatitis. *J Am Acad Dermatol* **28**:189, 1993 [PMID 8432915]
89. Schneider LC et al: Long-term therapy with recombinant interferon-gamma (rIFN-gamma) for atopic dermatitis. *Ann Allergy Asthma Immunol* **80**:263, 1998 [PMID 9532976]
90. Stevens SR et al: Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels. *Arch Dermatol* **134**:799, 1998 [PMID 9681342]
91. Krathen RA, Hsu S: Failure of omalizumab for treatment of severe adult atopic dermatitis. *J Am Acad Dermatol* **53**:338, 2005 [PMID 16021135]
92. Lane JE et al: Treatment of recalcitrant atopic dermatitis with omalizumab. *J Am Acad Dermatol* **54**:68, 2006 [PMID 16384758]
93. Belloni B et al: Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. *J Allergy Clin Immunol* **120**:1223, 2007 [PMID 17936892]
94. Werfel T et al: Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: A multi-centre, randomized, dose-response study. *Allergy* **61**:202, 2006 [PMID 16409197]
95. Pajno GB et al: Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: A randomized, double-blind, placebo-controlled study. *J Allergy Clin Immunol* **120**:164, 2007 [PMID 17543376]
96. Richter HI et al: Successful monotherapy of severe and intractable atopic dermatitis by photopheresis. *J Am Acad Dermatol* **38**(4):585-588, 1998
97. Kalliomaki M et al: Probiotics in primary prevention of atopic disease: A randomised placebo-controlled trial. *Lancet* **357**:1076, 2001 [PMID 11297958]
98. Kalliomaki M et al: Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. *Lancet* **361**:1869, 2003 [PMID 12788576]

99. Rosenfeldt V et al: Effect of probiotic Lactobacillus strains in children with atopic dermatitis. *J Allergy Clin Immunol* **111**:389, 2003 [PMID 12589361]
100. Weston S et al: Effects of probiotics on atopic dermatitis: A randomised controlled trial. *Arch Dis Child* **90**:892, 2005 [PMID 15863468]
101. Smits HH et al: Selective probiotic bacteria induce IL-10-producing regulatory T cells *in vitro* by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. *J Allergy Clin Immunol* **115**:1260, 2005 [PMID 15940144]
102. Michail SK et al: Efficacy of probiotics in the treatment of pediatric atopic dermatitis: A meta-analysis of randomized controlled trials. *Ann Allergy Asthma Immunol* **101**:508, 2008 [PMID 19055205]
103. Lee J, Seto D, Bielory L: Meta-analysis of clinical trials of probiotics for prevention and treatment of pediatric atopic dermatitis. *J Allergy Clin Immunol* **121**:116, 2008 [PMID 18206506]
104. Kopp MV et al: Randomized, double-blind, placebo-controlled trial of probiotics for primary prevention: No clinical effects of Lactobacillus GG supplementation. *Pediatrics* **121**:e850, 2008 [PMID 18332075]
105. Boyle RJ et al: Probiotics for treating eczema. *Cochrane Database Syst Rev* CD006135, 2008 [PMID 18843705]
106. Sidbury R et al: Randomized controlled trial of vitamin D supplementation for winter-related atopic dermatitis in Boston: A pilot study. *Br J Dermatol* **159**:245, 2008 [PMID 18489598]
107. Hata TR et al: Administration of oral vitamin D induces cathelicidin production in atopic individuals. *J Allergy Clin Immunol* **122**:829, 2008 [PMID 19014773]
108. Miller J, Gallo RL: Vitamin D and innate immunity. *Dermatol Ther* **23**:13, 2010 [PMID 20136905]
109. Staab D et al: Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: Multi-centre, randomised controlled trial. *BMJ* **332**:933, 2006 [PMID: 16627509]